138663-29-3

Upstream product

• 111605-09-5 (3S,4S-trans)-1,3,4,5-tetrahydro-6-(trifluoromethyl)-3-(methoxycarbonyl)-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one 
• 111605-10-8 (3S,4R)-1-Methoxymethyl-4-(4-methoxy-phenyl)-2-oxo-6-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-3-carboxylic acid methyl ester 
• 111604-99-0 [1-(4-Methoxyphenyl)-2-[2-nitro-6-(trifluoromethyl)phenyl]ethyl]propanedioic acid,dimethyl ester 
• 138383-10-5 1,3,4,5-tetrahydro-6-(trifluoromethyl)-3-(methoxycarbonyl)-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one 
• 111605-05-1 [2-(2-amino-6-trifluoromethylphenyl)-1-(4-methoxyphenyl)ethyl]propanedioic acid,dimethyl ester 
• 111605-14-2 (3S,4S)-3-Ethyl-1-methoxymethyl-4-(4-methoxy-phenyl)-2-oxo-6-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-3-carboxylic acid methyl ester 
• 111605-10-8 (3S,4S)-1,3,4,5-tetrahydro-3-(methoxycarbonyl)-1-(methoxymethyl)-4-(4-methoxyphenyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one 
• 111605-14-2 (3R,4S)-3-Ethyl-1-methoxymethyl-4-(4-methoxy-phenyl)-2-oxo-6-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-3-carboxylic acid methyl ester 
• 6656-49-1 2-methyl-1-nitro-3-(trifluoromethyl)benzene 
• 7443-25-6 dimethyl 2-(4-methoxybenzylidene)malonate 

Downstream Products

• 138664-51-4 (3S,4R)-1-(2-Dimethylamino-ethyl)-3-ethyl-4-(4-methoxy-phenyl)-6-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 119217-15-1 (3R,4R)-1-(2-Dimethylamino-ethyl)-3-ethyl-4-(4-methoxy-phenyl)-6-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 119217-15-1 (3S,4S)-1-(2-Dimethylamino-ethyl)-3-ethyl-4-(4-methoxy-phenyl)-6-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 111605-16-4 (R)-3-Ethyl-4-(4-methoxy-phenyl)-6-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 111605-16-4 (3S,4S)-3-Ethyl-4-(4-methoxy-phenyl)-6-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 

Relevant academic research and scientific papers

Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site

We have synthesized a series of benzazepinones (2) in order to determine the structure-activity relationships (SAR) for calcium channel blockers related to diltiazem. A prerequisite for calcium channel blocking activity in vitro and in vivo is the presenc

Benzazepinone Calcium Channel Blockers. 3. Synthesis and Structure-Activity Studies of 3-Alkylbenzazepinones

As part of a program aimed at identifying novel analogues of diltiazem, we developed several synthetic routes for 3-alkylbenzazepinones, both in racemic and nonracemic form.Structure-activity relationship studies in this series have led to identification